Market overview
The global breast cancer grading tools market is worth USD 102 mn in 2026 and is forecast to reach USD 490 mn by 2036, growing at a 17.0% CAGR. United States is the largest country market and Histologic grading is the largest by task segment.
| Scope | AI software that supports breast cancer pathology: histologic grading, HER2 and Ki-67 scoring and lymph node or margin assessment on digital slides, sold to pathology labs and hospitals. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 85 mn |
| Value 2026 | USD 102 mn |
| Value 2036 | USD 490 mn |
| CAGR 2026-2036 | 17.0% |
| Volume 2026 | 2.57 million analyses |
| Volume 2036 | 15.1 million analyses |
| Average price 2026 | USD 39.7 per analyse |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Breast Cancer Grading Tools market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 102 mn |
| 2027 | USD 119 mn |
| 2028 | USD 140 mn |
| 2029 | USD 163 mn |
| 2030 | USD 191 mn |
| 2031 | USD 224 mn |
| 2032 | USD 262 mn |
| 2033 | USD 306 mn |
| 2034 | USD 358 mn |
| 2035 | USD 419 mn |
| 2036 | USD 490 mn |
Breast Cancer Grading Tools market segmentation
By task
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Histologic grading | 40.0% | 36.7% | USD 41 mn | 16.0% |
| HER2 and Ki-67 scoring | 36.0% | 39.2% | USD 37 mn | 18.0% |
| Lymph node and margin assessment | 24.0% | 24.0% | USD 24 mn | 17.0% |
By deployment
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Cloud | 48.0% | 57.5% | USD 49 mn | 19.1% |
| On-premise | 34.0% | 24.3% | USD 35 mn | 13.1% |
| Embedded in scanner or laboratory system | 18.0% | 18.2% | USD 18 mn | 17.1% |
By technology
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Deep learning | 62.0% | 70.0% | USD 63 mn | 18.4% |
| Classical machine learning | 26.0% | 20.0% | USD 27 mn | 14.0% |
| Rule-based image analysis | 12.0% | 10.0% | USD 12 mn | 14.9% |
By sample
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| H and E stained slides | 56.0% | 52.0% | USD 57 mn | 16.1% |
| IHC slides | 30.0% | 31.0% | USD 31 mn | 17.4% |
| Mammography and radiology | 14.0% | 17.0% | USD 14 mn | 19.3% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospital pathology labs | 48.0% | 44.0% | USD 49 mn | 16.0% |
| Reference labs | 30.0% | 31.0% | USD 31 mn | 17.4% |
| Research institutes | 12.0% | 13.0% | USD 12 mn | 17.9% |
| Pharma | 10.0% | 12.0% | USD 10 mn | 19.1% |
Top 25 countries for breast cancer grading tools by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 80.0% of 2026 revenue and the 25 countries below together hold 96.0%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 39 mn | 38.0% | USD 188 mn | 17.1% |
| 2 | China | USD 8.2 mn | 8.0% | USD 47 mn | 19.1% |
| 3 | Germany | USD 7.1 mn | 7.0% | USD 32 mn | 16.1% |
| 4 | United Kingdom | USD 7.1 mn | 7.0% | USD 33 mn | 16.7% |
| 5 | France | USD 4.1 mn | 4.0% | USD 18 mn | 16.1% |
| 6 | Japan | USD 4.1 mn | 4.0% | USD 17 mn | 15.4% |
| 7 | Israel | USD 3.1 mn | 3.0% | USD 15 mn | 17.0% |
| 8 | Italy | USD 3.1 mn | 3.0% | USD 13 mn | 15.8% |
| 9 | Netherlands | USD 3.1 mn | 3.0% | USD 14 mn | 16.6% |
| 10 | Canada | USD 3.1 mn | 3.0% | USD 14 mn | 16.6% |
| 11 | Spain | USD 3.0 mn | 2.9% | USD 14 mn | 16.9% |
| 12 | Sweden | USD 2.3 mn | 2.2% | USD 11 mn | 16.9% |
| 13 | Belgium | USD 2.1 mn | 2.0% | USD 9.9 mn | 16.9% |
| 14 | Switzerland | USD 1.6 mn | 1.6% | USD 7.8 mn | 17.0% |
| 15 | Australia | USD 1.5 mn | 1.4% | USD 7.0 mn | 16.9% |
| 16 | Denmark | USD 1.1 mn | 1.1% | USD 5.4 mn | 16.9% |
| 17 | South Korea | USD 0.88 mn | 0.9% | USD 4.7 mn | 18.3% |
| 18 | Brazil | USD 0.73 mn | 0.7% | USD 4.0 mn | 18.4% |
| 19 | India | USD 0.73 mn | 0.7% | USD 3.9 mn | 18.2% |
| 20 | Singapore | USD 0.66 mn | 0.7% | USD 3.6 mn | 18.4% |
| 21 | Taiwan | USD 0.48 mn | 0.5% | USD 2.5 mn | 18.2% |
| 22 | Austria | USD 0.37 mn | 0.4% | USD 1.8 mn | 17.0% |
| 23 | Finland | USD 0.37 mn | 0.4% | USD 1.8 mn | 17.0% |
| 24 | Poland | USD 0.29 mn | 0.3% | USD 1.5 mn | 18.2% |
| 25 | Norway | USD 0.26 mn | 0.2% | USD 1.2 mn | 17.0% |
| Rest of world | USD 4.1 mn | 4.0% | USD 18 mn | 16.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Roche
- Philips
- Leica Biosystems
Group 2: Regional and specialist players
- Ibex Medical Analytics
- Visiopharm
- Aiforia
- Indica Labs
- 3DHISTECH
- Techcyte
Group 3: Emerging and niche players
- Paige
- Lunit
- PathAI
- Proscia
- Mindpeak
- Deep Bio
- Tribun Health
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the breast cancer grading tools market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 17.0% is calculated from the resulting values.
The market is divided by task, by deployment, by technology, by sample, by end user. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the breast cancer grading tools market?
The global breast cancer grading tools market is estimated at USD 85 mn in 2025 and USD 102 mn in 2026.
How fast will the breast cancer grading tools market grow?
It is forecast to reach USD 490 mn by 2036, a compound annual growth rate of 17.0% from 2026, an increase of USD 388 mn.
Which country is the largest market for breast cancer grading tools?
United States is the largest market by revenue at USD 39 mn in 2026, 38.0% of the global total. The three largest countries together hold 53.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 19.1% a year from 2026 to 2036.
Which breast cancer grading tools segment is largest?
In the by task split, Histologic grading is the largest segment with 40.0% of 2026 revenue.
Who are the leading breast cancer grading tools companies?
Global leaders include Roche, Philips, Leica Biosystems.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Federated Learning Drug DiscoveryUSD 104 mn · 20.0% CAGR
- Brachytherapy Treatment Planning SystemsUSD 95 mn · 5.8% CAGR
- Isokinetic Diagnostic and Training SystemUSD 110 mn · 5.5% CAGR
- Ostomy Irrigation ProductsUSD 94 mn · 4.3% CAGR
- Bioabsorbable StentsUSD 92 mn · 7.0% CAGR
- Aquaculture Fungal Infection TreatmentUSD 90 mn · 6.0% CAGR
- Medical Telepresence RobotsUSD 119 mn · 8.0% CAGR
- Impedance-based TEER Measurement SystemUSD 120 mn · 9.0% CAGR
← Brachytherapy Treatment Planning Systems CRISPR and Cas Gene →